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Abstract 
Objective: (State your objective). Methods: (Describe your methods). Results: (Provide your 
results). 
Cardiovascular disease is a widely diagnosed condition that can have many etiologies and factors 
that changes its prognosis. This project was aimed at investigating two potential factors that 
changes its prognosis: HIV status and gender. Data on HIV status was collected from NCHHSTP 
AtlasPlus for all US states and territories and data on cardiovascular disease deaths and 
corresponding gender was collected from Interactive Atlas of Heart Disease and Stroke for all 
US states and territories. Using a linear regression test, a correlation was tested for between HIV 
status and cardiovascular disease deaths for every US state/territory followed by a test between 
gender and cardiovascular disease deaths for every US state/territory. The study did not yield 
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significant results between HIV status and cardiovascular disease deaths, a rise in .006 deaths for 
every case of HIV, however it did yield statistically significant data between gender and 
cardiovascular disease deaths, 161 fewer deaths per thousand in females versus males.  
Key Words: cardiovascular disease, HIV, mortality 
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Introduction/Literature Review  
Cardiovascular disease has been a significant diagnosis made in the United States due to how 
drastically it affects the day to day life of the person diagnosed with it. It is also a diagnosis that 
is being made more frequently due to its association with obesity and hypertension which are 
concurrently on the rise. To minimize its prevalence, it is important to investigate what factors 
are associated with cardiovascular disease; One possible factor that can be associated with 
cardiovascular disease is HIV. In a study conducted on biventricular heart function on adults 
with Human Immunodeficiency Virus (HIV) infection, a correlation was found between 
echocardiograph detected ventricular wall deformation and having HIV 1. Therefore, there is 
evidence that HIV status can possibly lead to subclinical myocardial dysfunction.  
A separate study also found a positive correlation between HIV status and cardiovascular 
disease, in the form of ischemic electrocardiography by gender 2. According to this study, 
women who were HIV positive were at twice the risk of having myocardial ischemia compared 
to men who were HIV positive. Therefore, it will be important to monitor HIV patients more 
carefully according to gender due to an increased risk for cardiovascular disease for women. One 
of the cardiovascular complications that can arise in HIV patients is a risk for atrial fibrillation 
which can lead to thromboembolisms and consequent brain strokes 3. Therefore, HIV patients 
had an increased risk of ischemic stroke and systemic embolism along with major bleeding as 
cardiovascular complications compared to patients without HIV.  
If a correlation is found between HIV and cardiovascular risk, a treatment plan needs to be 
devised to provide patients with a way to minimize the severity of their cardiovascular disease. 
One study investigated a possible treatment route by assessing the effectiveness of an 8 week 
aerobic exercise program on heart rate variability in people living with HIV taking anti-retroviral 
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therapy (ART), the researchers were unable to conclude that aerobic exercise had an effect on 
heart rate variability but were able to obtain data that suggested overall autonomic function 
improved across time with aerobic exercise 4. While it has already been suggested that exercise 
has positive effects on mortality in obesity and hypertension prognosis, due to their exacerbation 
being major factors leading to cardiovascular disease, it is also a significant finding that aerobic 
exercise can positively impact the prognosis of cardiovascular disease in HIV patients; thereby 
providing emphasizing the role of aerobic exercise as a potential treatment route for patients with 
cardiovascular disease and HIV. Another study investigated an alternative treatment plan by 
studying immature platelet function (IPF) of HIV patients who were on ART. According to a 
previous research study done, IPF was increased in HIV negative patients with cardiovascular 
disease which was associated with adverse cardiovascular events, however patients with HIV on 
ART showed lower immature platelet function 5. The study concluded that a reduction in IPF 
could only be obtained with administration of ART in the absence of cardiovascular disease and 
that the presence of cardiovascular disease hindered any significant reduction in IPF, however 
the researchers of this study suggested a future investigation to be done to determine if an 
increased IPF can be used as a biomarker for predicting adverse cardiovascular events in HIV 
patients. If patients present with an enlarged IPF, this biomarker could serve as a protective 
warning sign against a potential adverse cardiovascular event.  
 
Hypothesis/Specific Aims/Research Questions 
Numerous research data has suggested that HIV prevalence is associated and positively 
correlated with cardiovascular disease deaths, but little has been done to suggest how HIV status 
affects the outcome of cardiovascular disease. I hypothesize a positive correlation between HIV 
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prevalence and deaths from cardiovascular disease by way of HIV exacerbating cardiovascular 
disease thereby outlining a cause and effect. Additionally I hypothesize a difference in 
cardiovascular disease prognosis between male and female gender. 
Methods 
Context/Protocol 
I utilized data from human subjects that was already available on the CDC wonder public 
data set.  
Data Collection 
In order to investigate the effect HIV status and gender has on cardiovascular disease 
outcome, I collected data on 3 variables: HIV prevalence, gender, and cardiovascular disease 
deaths in all US states and territories. HIV prevalence was available on the NCHHSTP AtlasPlus 
data on HIV prevalence between 2014 and 2016 for ages 13 years and older for all races, sexes, 
and transmission categories. I collected cardiovascular disease death data and the gender for the 
corresponding data set on the Interactive Atlas of Heart Disease and Stroke for all US states and 
territories. The three variables I will analyze will be number of cases of HIV in each US state or 
dependent area compared to number of deaths due to cardiovascular disease in that same US 
state or dependent area compared to gender.  
Data Analysis 
A linear regression test paired the HIV prevalence and cardiovascular disease deaths data to 
assess for a correlation between HIV prevalence and cardiovascular disease deaths. A p-value of 
less than .05 was considered statistically significant and suggested that HIV status has been 
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observed to worsen the prognosis of cardiovascular disease. The linear regression test assessed 
for a correlation between gender and cardiovascular disease deaths. The data was inputted such 
that males had a numerical value of 1 and females had a numerical value of 2. A p-value of less 
than .05 was again considered statistically significant and suggested that cardiovascular disease 
is exacerbated by the gender given the higher numerical value: female, in this study. 
Results 
Table 1: Cardiovascular Disease Deaths, HIV Prevalence, and Gender descriptive 
statistics 
Category Mean Standard 
Deviation 
Sample Size (N) 
Cardiovascular 
Disease Deaths 
441.07 120.45 112 
HIV Prevalence 308.37 421.06 112 
Gender 1.5  .50225 112 
 
Table 1 lists the descriptive statistics given by the linear regression analysis. Of the 112 
samples, the mean number of cardiovascular disease deaths was 441.07 per US state or 
region. The mean number of HIV cases in each state or region was 308.37. Finally, the 
mean value of gender was 1.5, between males having a value of 1 and females having a 
value of 2, indicating equal representation of male and female sample data.  
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Table 2: Correlations between Cardiovascular Disease Deaths, HIV Prevalence, and 
Gender 
Category Cardiovascular 
Disease Deaths 
HIV Prevalence Gender 
Cardiovascular 
Disease Deaths 
1.00 .27 -.68 
HIV Prevalence .27 1.00 -.37 
Gender -.68 -.37 1.00 
 
Table 2 states the correlation values obtained by the linear regression analysis. 
Cardiovascular disease deaths had a correlation of .27 with HIV prevalence and a -.68 
correlation with Gender. HIV prevalence had a -.37 correlation with Gender.  
 
Table 3: Linear Regression Results for HIV Prevalence and Gender vs Cardiovascular 
Disease Deaths 
Category B value Standard Error Significance value 
(alpha=.05) 
HIV Prevalence .006 .022 .77 
Gender -161.85 18.05 .00 
 
Table 2 lists the B values obtained by the linear regression analysis. HIV prevalence was 
not shown to have a statistically significant value at .006. Gender was shown to have a 
statistically significant value of -161.85. 
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Discussion 
Although Table 2 demonstrates a positive correlation between HIV prevalence and 
cardiovascular disease deaths, the correlation is small and the B value of .006 is deemed 
statistically insignificant by the set alpha value of .05. The minor interpretation to be made is 
that for every new case of HIV, the mean number of cardiovascular disease deaths that rise is 
approximately 0.006 per thousand. The more significant finding of this study was highlighted 
by B value of the gender vs cardiovascular disease deaths analysis. Using an alpha of 0.05, it 
was found to be statistically significant with a value of -161.85. This indicated that for every 
point increase in gender, going from male to female, the number of cardiovascular disease 
deaths decreased by approximately 161.85 cases per thousand. This result contradicts much 
of the literature that suggest women having a higher risk of developing cardiovascular 
disease than men such as in the earlier mentioned study in which HIV positive women had 
twice the likelihood of HIV positive men in developing a worse cardiovascular outcome 2. 
Upon further investigation however, there has been evidence to suggest that estrogen can be 
attributed as the protective factor in women. A study conducted on the gender differences in 
coronary heart disease found that women tend to develop cardiovascular disease 7 to 10 years 
later than men but women who had an endogenous estrogen deficiency had a sevenfold 
increase in coronary artery disk risk. Estrogen was claimed to have a protective factor against 
heart disease due to its regulatory effect on lipids, inflammatory markers, and the coagulant 
system in addition to its direct vasodilatory effects through the alpha and beta receptors in the 
vessel wall 6. An additional study attributed estrogen’s cardioprotective results to its 
interaction with the E2 receptor. In this study, heart failure and ischemic heart injury were 
linked to bioenergetic abnormalities such as mitochondrial homeostasis. The estrogen 
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activated E2 receptor can trigger transcriptional changes in nuclear and mitochondrial genes 
to positively influence mitochondrial function and cell survival thereby offering cardio-
protection 7. Although this is a preliminary finding, if further investigation confirms the 
protective role of estrogen, then the potential exists for artificial estrogen to stimulate the E2 
receptor and protect the population with risk factors for cardiovascular disease or those with 
a bad prognosis of cardiovascular disease. 
Conclusion 
Although the results of this study conclude that HIV does not affect cardiovascular disease 
prognosis and that women have a more favorable prognosis with cardiovascular disease 
prognosis, the design of the study faces limitations thereby preventing these results from 
being definitive. The linear regression test used means that the data used pertained to an 
entire state rather than a single person. Therefore, the same patients who were diagnosed with 
HIV were not necessarily the same patients who died from or survived cardiovascular disease 
or were even diagnosed with it. This means that there could still be a causal effect between 
HIV and cardiovascular disease, as the literature suggest. Furthermore, gender may also not 
affect cardiovascular disease due to the same limitation of a linear regression test. Future 
studies should be conducted in order to further investigate these potential relationships 
between HIV with cardiovascular disease and gender with cardiovascular disease. Much of 
the literature seems to suggest an association between HIV and cardiovascular disease, and if 
a true causal relationship can be established, it may necessitate cardiovascular disease 
preventative measures. Additionally, if a relationship between gender and cardiovascular 
disease can be causally established, the vulnerable gender can also be given subsequent 
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cardioprotective measures. With these additional steps, numerous cases of cardiovascular 
disease can be prevented.   
  
 Ahmad  11 
 
References 
1.  Capotosto L, D’Ettorre G, Ajassa C, et al. Assessment of Biventricular Function by Three-
Dimensional Speckle Tracking Echocardiography in Adolescents and Young Adults with 
Human Immunodeficiency Virus Infection: A Pilot Study. Cardiology. October 2019:1-
11. doi:10.1159/000503140 
2.  Kentoffio K, Albano A, Koplan B, et al. Electrocardiographic Evidence of Cardiac 
Disease by Sex and HIV Serostatus in Mbarara, Uganda. Glob Heart. October 2019. 
doi:10.1016/j.gheart.2019.08.007 
3.  Jung H, Yang P-S, Jang E, et al. Prevalence and Associated Stroke Risk of Human 
Immunodeficiency Virus-Infected Patients With Atrial Fibrillation ― A Nationwide 
Cohort Study ―. Circ J. October 2019. doi:10.1253/circj.CJ-19-0527 
4.  Quiles N, Taylor BS, Ortiz A. Effectiveness of an 8-week aerobic exercise program on 
autonomic function in people living with HIV taking Anti-retroviral therapy: A pilot 
randomized controlled trial. AIDS Res Hum Retroviruses. October 2019. 
doi:10.1089/aid.2019.0194 
5.  Goedel A, Müller S, Schwerdtfeger C, et al. Influence of antiretroviral therapy and 
cardiovascular disease on the immature platelet fraction in patients living with HIV. 
Platelets. October 2019:1-7. doi:10.1080/09537104.2019.1678114 
6.  Maas AHEM, Appelman YEA. Gender differences in coronary heart disease. Neth Heart 
J. 2010;18(12):598-602. doi:10.1007/s12471-010-0841-y 
7.  Iorga A, Cunningham CM, Moazeni S, Ruffenach G, Umar S, Eghbali M. The protective 
 Ahmad  12 
 
role of estrogen and estrogen receptors in cardiovascular disease and the controversial use 
of estrogen therapy. Biol Sex Differ. 2017;8(1):33. doi:10.1186/s13293-017-0152-8 
 
 
